187 related articles for article (PubMed ID: 31362937)
1. Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer.
Blanchard Z; Vahrenkamp JM; Berrett KC; Arnesen S; Gertz J
Genome Res; 2019 Sep; 29(9):1429-1441. PubMed ID: 31362937
[TBL] [Abstract][Full Text] [Related]
2. Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha-Mutant Endometrial Cancer.
Blanchard Z; Rush CM; Arnesen S; Vahrenkamp JM; Rodriguez AC; Jarboe EA; Brown C; Chang MEK; Flory MR; Mohammed H; Modzelewska K; Lum DH; Gertz J
Mol Cancer Res; 2023 Oct; 21(10):1023-1036. PubMed ID: 37363949
[TBL] [Abstract][Full Text] [Related]
3. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
[TBL] [Abstract][Full Text] [Related]
5. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
6. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
8. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
[TBL] [Abstract][Full Text] [Related]
9. Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in
Hosfield DJ; Weber S; Li NS; Sauvage M; Joiner CF; Hancock GR; Sullivan EA; Ndukwe E; Han R; Cush S; Lainé M; Mader SC; Greene GL; Fanning SW
Elife; 2022 May; 11():. PubMed ID: 35575456
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
Drouyer A; Beaussire L; Jorda P; Leheurteur M; Guillemet C; Berghian A; Georgescu D; Di Fiore F; Perdrix A; Clatot F
BMC Cancer; 2023 Nov; 23(1):1061. PubMed ID: 37924026
[TBL] [Abstract][Full Text] [Related]
11. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 Reprogramming Dictates Retinoid X Receptor Response in ESR1-Mutant Breast Cancer.
Wu Y; Li Z; Wedn AM; Casey AN; Brown D; Rao SV; Omarjee S; Hooda J; Carroll JS; Gertz J; Atkinson JM; Lee AV; Oesterreich S
Mol Cancer Res; 2023 Jun; 21(6):591-604. PubMed ID: 36930833
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
14. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
[TBL] [Abstract][Full Text] [Related]
15. ESR1 Mutations Associated With Estrogen Insensitivity Syndrome Change Conformation of Ligand-Receptor Complex and Altered Transcriptome Profile.
Li Y; Hamilton KJ; Perera L; Wang T; Gruzdev A; Jefferson TB; Zhang AX; Mathura E; Gerrish KE; Wharey L; Martin NP; Li JL; Korach KS
Endocrinology; 2020 Jun; 161(6):. PubMed ID: 32242619
[TBL] [Abstract][Full Text] [Related]
16. Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Harrod A; Lai CF; Goldsbrough I; Simmons GM; Oppermans N; Santos DB; Győrffy B; Allsopp RC; Toghill BJ; Balachandran K; Lawson M; Morrow CJ; Surakala M; Carnevalli LS; Zhang P; Guttery DS; Shaw JA; Coombes RC; Buluwela L; Ali S
Oncogene; 2022 Oct; 41(44):4905-4915. PubMed ID: 36198774
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
[TBL] [Abstract][Full Text] [Related]
18. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
[TBL] [Abstract][Full Text] [Related]
19. ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells.
Rodriguez AC; Vahrenkamp JM; Berrett KC; Clark KA; Guillen KP; Scherer SD; Yang CH; Welm BE; Janát-Amsbury MM; Graves BJ; Gertz J
Cancer Res; 2020 Mar; 80(6):1234-1245. PubMed ID: 32046982
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer.
Backes FJ; Walker CJ; Goodfellow PJ; Hade EM; Agarwal G; Mutch D; Cohn DE; Suarez AA
Gynecol Oncol; 2016 May; 141(2):312-317. PubMed ID: 26957478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
